Welcome to LookChem.com Sign In|Join Free
  • or
3-(BENZYLOXY)-2-HYDROXYPROPANOIC ACID, also known as (R)-3-(Benzyloxy)-2-hydroxypropanoic Acid, is an organic compound with the molecular formula C10H12O4. It is a derivative of hydroxypropanoic acid, featuring a benzyloxy group attached to the third carbon and a hydroxyl group on the second carbon. 3-(BENZYLOXY)-2-HYDROXYPROPANOIC ACID is known for its potential applications in various industries due to its unique structural properties.

130111-08-9

Post Buying Request

130111-08-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

130111-08-9 Usage

Uses

Used in Pharmaceutical Industry:
3-(BENZYLOXY)-2-HYDROXYPROPANOIC ACID is used as a reactant for the synthetic preparation of 2-Oxopiperazine derivatives, which are important in the development of pharmaceutical compounds. The application reason is that these derivatives have shown potential in various therapeutic areas, including the treatment of central nervous system disorders, cardiovascular diseases, and certain types of cancer.
Used in Chemical Synthesis:
In the field of chemical synthesis, 3-(BENZYLOXY)-2-HYDROXYPROPANOIC ACID serves as a versatile building block for the creation of more complex molecules. The application reason is its unique structural features, which allow for further functionalization and the formation of a wide range of compounds with diverse properties and potential applications.
Used in Research and Development:
3-(BENZYLOXY)-2-HYDROXYPROPANOIC ACID is also used as a research compound in academic and industrial laboratories. The application reason is to explore its chemical properties, reactivity, and potential applications in various fields, such as materials science, pharmaceuticals, and agrochemicals.

Check Digit Verification of cas no

The CAS Registry Mumber 130111-08-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,1,1 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 130111-08:
(8*1)+(7*3)+(6*0)+(5*1)+(4*1)+(3*1)+(2*0)+(1*8)=49
49 % 10 = 9
So 130111-08-9 is a valid CAS Registry Number.

130111-08-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name HO-Ser(Bn)-OH

1.2 Other means of identification

Product number -
Other names (2S)-3-bezyloxy-2-hidroxy propanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:130111-08-9 SDS

130111-08-9Relevant academic research and scientific papers

Targeting the APP-Mint2 Protein-Protein Interaction with a Peptide-Based Inhibitor Reduces Amyloid-β Formation

Bartling, Christian R. O.,Jensen, Thomas M. T.,Henry, Shawna M.,Colliander, Anna L.,Sereikaite, Vita,Wenzler, Marcella,Jain, Palash,Maric, Hans M.,Harps?e, Kasper,Pedersen, S?ren W.,Clemmensen, Louise S.,Haugaard-Kedstr?m, Linda M.,Gloriam, David E.,Ho, Angela,Str?mgaard, Kristian

supporting information, p. 891 - 901 (2021/02/05)

There is an urgent need for novel therapeutic approaches to treat Alzheimer's disease (AD) with the ability to both alleviate the clinical symptoms and halt the progression of the disease. AD is characterized by the accumulation of amyloid-β (Aβ) peptides

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

-

Page/Page column 491, (2021/06/26)

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

Total Synthesis of the Cyclic Depsipeptide Vioprolide D via its (Z)-Diastereoisomer

Bach, Thorsten,Grab, Hanusch A.,Kirsch, Volker C.,Sieber, Stephan A.

supporting information, p. 12357 - 12361 (2020/05/05)

The first total synthesis of vioprolide D was accomplished in an overall yield of 2.0 % starting from methyl (2S)-3-benzyloxy-2-hydroxypropanoate (16 steps in the longest linear sequence). The cyclic depsipeptide was assembled from two building blocks of

Synthesis of carbohydrate-grafted glycopolymers using a catalyst-free, perfluoroarylazide-mediated fast staudinger reaction

Ndugire, William,Wu, Bin,Yan, Mingdi

, (2019/01/21)

Glycopolymers have gained increasing importance in investigating glycan-lectin interactions, as drug delivery vehicles and in modulating interactions with proteins. The synthesis of these glycopolymers is still a challenging and rigorous exercise. In this

JAK1 SELECTIVE INHIBITORS

-

Page/Page column 64; 65, (2018/08/12)

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS

-

Paragraph 0211, (2017/12/09)

The disclosure provides compounds of the formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables A, R1, and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering to a patient infected with the bacteria, simultaneously or sequentially, a therapeutically effective amount of the antibacterial agent and a compound of formula (I).

Facile synthesis of α-hydroxy carboxylic acids from the corresponding α-amino acids

Stuhr-Hansen, Nicolai,Padrah, Shahrokh,Str?mgaard, Kristian

supporting information, p. 4149 - 4151 (2015/02/02)

An effective and improved procedure is developed for the synthesis of α-hydroxy carboxylic acids by treatment of the corresponding protonated α-amino acid with tert-butyl nitrite in 1,4-dioxane-water. The amino moiety must be protonated and located α to a carboxylic acid function in order to undergo initial diazotization and successive hydroxylation, since neither β-amino acids nor acid derivatives such as esters and amides undergo hydroxylations. The method is successfully applied for the synthesis of 18 proteinogenic amino acids.

Facile synthesis of α-hydroxy carboxylic acids from the corresponding α-amino acids

Stuhr-Hansen, Nicolai,Padrah, Shahrokh,Str?mgaard, Kristian

supporting information, p. 4149 - 4151 (2014/07/22)

An effective and improved procedure is developed for the synthesis of α-hydroxy carboxylic acids by treatment of the corresponding protonated α-amino acid with tert-butyl nitrite in 1,4-dioxane-water. The amino moiety must be protonated and located α to a carboxylic acid function in order to undergo initial diazotization and successive hydroxylation, since neither β-amino acids nor acid derivatives such as esters and amides undergo hydroxylations. The method is successfully applied for the synthesis of 18 proteinogenic amino acids.

Glycan arrays containing synthetic Clostridium difficile lipoteichoic acid oligomers as tools toward a carbohydrate vaccine

Martin, Christopher E.,Broecker, Felix,Eller, Steffen,Oberli, Matthias A.,Anish, Chakkumkal,Pereira, Claney L.,Seeberger, Peter H.

supporting information, p. 7159 - 7161 (2013/08/23)

Clostridium difficile is a leading cause of severe nosocomial infections. Cell-surface carbohydrate antigens are promising vaccine candidates. Here we report the first total synthesis of oligomers of the lipoteichoic acid antigen repeating unit. Synthetic glycan microarrays revealed anti-glycan antibodies in the blood of patients that help to define epitopes for vaccine development.

In vitro chemoenzymatic and in vivo biocatalytic syntheses of new beauvericin analogues

Matthes, Diana,Richter, Lennart,Mueller, Jane,Denisiuk, Alexander,Feifel, Sven C.,Xu, Yuquan,Espinosa-Artiles, Patricia,Suessmuth, Roderich D.,Molnar, Istvan

supporting information; experimental part, p. 5674 - 5676 (2012/07/27)

New beauvericins have been synthesized using the nonribosomal peptide synthetase BbBEAS from the entomopathogenic fungus Beauveria bassiana. Chemical diversity was generated by in vitro chemoenzymatic and in vivo whole cell biocatalytic syntheses using ei

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 130111-08-9